江苏自贸区生物医药迎全产业链发展

Core Viewpoint - The Jiangsu Free Trade Zone is set to enhance the entire biopharmaceutical industry chain through innovative development, aiming to bridge the gap between laboratory research and clinical application, while also connecting domestic innovation with international markets [1][2]. Group 1: Policy and Implementation - The "Biopharmaceutical Industry Chain Open Innovation Development Plan" has been approved by the State Council, marking Jiangsu as the first province to initiate such a comprehensive reform in the biopharmaceutical sector [1][2]. - The implementation plan includes 18 specific measures across six areas: enhancing R&D capabilities, improving product approval services, constructing a production and distribution system, refining procurement policies, increasing support for resources, and ensuring safety in development [2][3]. Group 2: Industry Strengths - Jiangsu accounts for 1/8 of the national biopharmaceutical industry, leading in both scale and innovation, with approximately 1/3 of innovative drugs approved in the country [3]. - The province's Free Trade Zone is a significant contributor, with half of the industry's output coming from its three designated areas, showcasing strong upstream and downstream capabilities [3]. Group 3: Global Integration and Talent Attraction - The plan facilitates international recognition of professional qualifications for foreign talent, allowing them to work in Jiangsu without the need for domestic certification [4]. - It encourages foreign physicians to provide services within the Free Trade Zone, enabling local residents to access high-quality international medical resources [4]. Group 4: Innovation and Development Focus - The initiative emphasizes cutting-edge fields such as gene and cell therapy and brain science, with plans to implement major national projects in these areas [5]. - Jiangsu aims to establish a national-level platform matrix for biopharmaceutical innovation, including a national biopharmaceutical technology innovation center and the largest gene sequencing matrix in Asia [5].